Abstract
Objectives To assess the accuracy of the Midmark IQvitals® Zone™ wireless vital signs monitor LINEAR deflation algorithm to the requirements of the ANSI/AAMI/ISO 81060-2 Standard and the British Hypertension Society (BHS) Protocol.
Methods The Standard and BHS testing each call for ≥ 85 subjects with requirements for gender, blood pressure (BP), and arm circumference. The testers performing auscultation were blinded. Statistical calculations as per requirements were performed.
Results The mean ± SD for the 81060-2 Criterion 1 were 1.98 ± 6.90 mmHg for systolic and 0.54 ± 5.79 mmHg for diastolic BP. The Criterion 2 SD values were 5.60 mmHg for systolic and 5.26 mmHg for diastolic BP. All of these values passed the Standard requirements. The overall BHS rating was AA.
Conclusions The Midmark LINEAR algorithm is validated based on the results. Use of the algorithm results in shorter cuff deflation times, thus improving patient comfort. The LINEAR algorithm has multiple features to improve BP measurement accuracy in critical patient populations.
Competing Interest Statement
Dr. Alpert is an expert consultant to Midmark Corporation.
Funding Statement
This study was funded by Midmark Corporation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Salus Institutional Review Board gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Retired
Data Availability
All data produced in the present study are available upon reasonable request to the author.